Please upgrade your browser

We built this website using the latest browser technologies to deliver the very best experience.

This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.

We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.

Download Microsoft EdgeDownload Microsoft Edge
Press release

Sensyne Health signs agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research

October 23, 2020

Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, today announces it has signed a research collaboration agreement with Bristol Myers Squibb (BMS).

Initially the collaboration will focus on applying Sensyne’s proprietary machine learning to conduct research into disease progression and patient stratification for patients with various diseases within the broader group of Myeloproliferative Neoplasms (MPNs). MPNs comprise a group of rare blood diseases characterised by the overproduction of one or more types of blood cells – red blood cells, white blood cells and platelets.

The collaboration will be Sensyne Health’s fourth successive partnership with a major pharmaceutical company following collaborations signed with Bayer, Roche and Alexion. No financial terms have been disclosed.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“This new collaboration with one of the world’s leading pharmaceutical companies is a further validation of Sensyne’s unique model whereby Sensyne acts as the docking station between the pharmaceutical industry and providers of health data to allow for the   ethical commercialisation of such data. As we continue to see wider adoption of Clinical AI and machine learning by the life sciences industry to support pharmaceutical research, Sensyne is ideally positioned to help accelerate the discovery and development of new medicines for patients.”

Press release

Sensyne Health signs agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research

October 23, 2020

Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, today announces it has signed a research collaboration agreement with Bristol Myers Squibb (BMS).

Initially the collaboration will focus on applying Sensyne’s proprietary machine learning to conduct research into disease progression and patient stratification for patients with various diseases within the broader group of Myeloproliferative Neoplasms (MPNs). MPNs comprise a group of rare blood diseases characterised by the overproduction of one or more types of blood cells – red blood cells, white blood cells and platelets.

The collaboration will be Sensyne Health’s fourth successive partnership with a major pharmaceutical company following collaborations signed with Bayer, Roche and Alexion. No financial terms have been disclosed.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“This new collaboration with one of the world’s leading pharmaceutical companies is a further validation of Sensyne’s unique model whereby Sensyne acts as the docking station between the pharmaceutical industry and providers of health data to allow for the   ethical commercialisation of such data. As we continue to see wider adoption of Clinical AI and machine learning by the life sciences industry to support pharmaceutical research, Sensyne is ideally positioned to help accelerate the discovery and development of new medicines for patients.”

Press release

Sensyne Health signs agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research

Sensyne Health signs agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research

October 23, 2020

Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, today announces it has signed a research collaboration agreement with Bristol Myers Squibb (BMS).

Initially the collaboration will focus on applying Sensyne’s proprietary machine learning to conduct research into disease progression and patient stratification for patients with various diseases within the broader group of Myeloproliferative Neoplasms (MPNs). MPNs comprise a group of rare blood diseases characterised by the overproduction of one or more types of blood cells – red blood cells, white blood cells and platelets.

The collaboration will be Sensyne Health’s fourth successive partnership with a major pharmaceutical company following collaborations signed with Bayer, Roche and Alexion. No financial terms have been disclosed.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“This new collaboration with one of the world’s leading pharmaceutical companies is a further validation of Sensyne’s unique model whereby Sensyne acts as the docking station between the pharmaceutical industry and providers of health data to allow for the   ethical commercialisation of such data. As we continue to see wider adoption of Clinical AI and machine learning by the life sciences industry to support pharmaceutical research, Sensyne is ideally positioned to help accelerate the discovery and development of new medicines for patients.”

Press release

Sensyne Health signs agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research

Sensyne Health signs agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research

Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, today announces it has signed a research collaboration agreement with Bristol Myers Squibb (BMS).

Initially the collaboration will focus on applying Sensyne’s proprietary machine learning to conduct research into disease progression and patient stratification for patients with various diseases within the broader group of Myeloproliferative Neoplasms (MPNs). MPNs comprise a group of rare blood diseases characterised by the overproduction of one or more types of blood cells – red blood cells, white blood cells and platelets.

The collaboration will be Sensyne Health’s fourth successive partnership with a major pharmaceutical company following collaborations signed with Bayer, Roche and Alexion. No financial terms have been disclosed.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“This new collaboration with one of the world’s leading pharmaceutical companies is a further validation of Sensyne’s unique model whereby Sensyne acts as the docking station between the pharmaceutical industry and providers of health data to allow for the   ethical commercialisation of such data. As we continue to see wider adoption of Clinical AI and machine learning by the life sciences industry to support pharmaceutical research, Sensyne is ideally positioned to help accelerate the discovery and development of new medicines for patients.”

Arrange to meet us
Press release

Sensyne Health signs agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research

October 23, 2020

Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, today announces it has signed a research collaboration agreement with Bristol Myers Squibb (BMS).

Initially the collaboration will focus on applying Sensyne’s proprietary machine learning to conduct research into disease progression and patient stratification for patients with various diseases within the broader group of Myeloproliferative Neoplasms (MPNs). MPNs comprise a group of rare blood diseases characterised by the overproduction of one or more types of blood cells – red blood cells, white blood cells and platelets.

The collaboration will be Sensyne Health’s fourth successive partnership with a major pharmaceutical company following collaborations signed with Bayer, Roche and Alexion. No financial terms have been disclosed.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“This new collaboration with one of the world’s leading pharmaceutical companies is a further validation of Sensyne’s unique model whereby Sensyne acts as the docking station between the pharmaceutical industry and providers of health data to allow for the   ethical commercialisation of such data. As we continue to see wider adoption of Clinical AI and machine learning by the life sciences industry to support pharmaceutical research, Sensyne is ideally positioned to help accelerate the discovery and development of new medicines for patients.”